Table 3.
Laboratory findings of patients infected with COVID-19.
| All patient | Disease Severity |
Reference | p value | ||
|---|---|---|---|---|---|
| Non-severe | Severe | ||||
| White blood cell count, ×10^9/L | 5.5(4.4−7.2) | 5.3(4.2−6.7) | 5.8(4.6−7.6) | 3.5−9.5 | <0.0001 |
| Increased | 140/1528(9.2) | 42/727(5.8) | 98/801(12.2) | <0.0001 | |
| Decreased | 147/1528(9.6) | 73/727(10.0) | 74/801(9.2) | 0.60 | |
| Lymphocyte count, ×10^9/L | 1.1(0.8−1.4) | 1.1(0.8−1.5) | 1.0(0.7−1.4) | 1.1−3.2 | 0.004 |
| Increased | 6/1528(0.4) | 4/727(0.6) | 2/801(0.3) | 0.43 | |
| Decreased | 780/1528(51.1) | 346/727(47.6) | 434/801(54.2) | 0.01 | |
| Lymphocyte percentage (%) | 20.8(13.4−28.3) | 21.8(14.6−29.3) | 19.5(11.8−27.4) | 20−50 | <0.0001 |
| Increased | 13/1528(0.9) | 7/727(1.0) | 6/801(0.8) | 0.65 | |
| Decreased | 718/1528(47.0) | 307/727(42.2) | 411/801(51.3) | 0.0004 | |
| Monocyte count, ×10^9/L | 0.5(0.4−0.6) | 0.5(0.4−0.6) | 0.5(0.4−0.6) | 0.1−0.6 | 0.62 |
| Increased | 406/1528(26.6) | 179/727(24.6) | 227/801(28.3) | 0.10 | |
| Decreased | 12/1528(0.8) | 3/727(0.4) | 9/801(1.1) | 0.12 | |
| Monocyte percentage (%) | 8.4(6.6−10.8) | 8.7(6.9−10.9) | 8.2(6.3−10.6) | 3.0−10.0 | 0.002 |
| Increased | 486/1528(31.8) | 247/727(34.0) | 239/801(29.8) | 0.08 | |
| Decreased | 63/1528(4.1) | 18/727(2.5) | 45/801(5.6) | 0.002 | |
| Neutrophil count, ×10^9/L | 3.8(2.7−5.3) | 3.6(2.6−4.9) | 3.9(2.8−5.7) | 1.8−6.3 | <0.0001 |
| Increased | 242/1528(15.8) | 79/727(10.9) | 163/801(20.4) | <0.0001 | |
| Decreased | 95/1528(6.2) | 50/727(6.9) | 45/801(5.6) | 0.31 | |
| Neutrophil percentage (%) | 68.9(60.2−78.2) | 67.4(59.0−75.9) | 70.8(60.8−79.7) | 40.0−75.0 | <0.0001 |
| Increased | 502/1528(32.9) | 202/727(27.8) | 300/801(37.5) | <0.0001 | |
| Decreased | 18/1528(1.2) | 11/727(1.5) | 7/801(0.9) | 0.25 | |
| Platelet count, ×10^9/L | 225.0(167.0−303.0) | 213.0(165.0−294.0) | 237.0(172.0−312.0) | 125−350 | 0.006 |
| Increased | 224/1523(14.7) | 87/723(12.0) | 137/800(17.1) | 0.005 | |
| Decreased | 130/1523(8.5) | 56/723(7.8) | 74/800(9.3) | 0.29 | |
| Hemoglobin, g/L | 127.0(116.0−137.0) | 128.0(118.0−138.0) | 126.0(115.0−137.0) | 130−175 | 0.003 |
| Decreased | 906/1528(59.3) | 408/727(56.1) | 498/801(62.2) | 0.02 | |
| Alanine aminotransferase, U/L | 23.0(15.0−37.0) | 22.0(14.0−37.0) | 24.0(15.0−37.0) | 4−41 | 0.09 |
| Increased | 298/1445(20.6) | 139/672(20.7) | 159/773(20.6) | 0.96 | |
| Aspartate aminotransferase, U/L | 26.0(19.0−38.0) | 25.0(19.0−36.0) | 27.0(20.0−39.0) | 4−40 | 0.02 |
| Increased | 303/1445(21.0) | 128/672(19.1) | 175/773(22.6) | 0.09 | |
| Albumin, g/L | 34.9(31.8−38.3) | 35.5(32.6−38.9) | 34.5(31.0−37.9) | 35−52 | <0.0001 |
| Decreased | 723/1443(50.1) | 306/672(45.5) | 417/771(54.1) | 0.001 | |
| Creatinine, umol/L | 68.0(57.0−83.0) | 67.0(56.0−82.0) | 68.0(58.0−84.0) | 59−104 | 0.17 |
| Increased | 119/1438(8.3) | 44/667(6.6) | 75/771(9.7) | 0.03 | |
| Urea, mmol/L | 4.3(3.4−5.6) | 4.1(3.2−5.2) | 4.6(3.5−6.1) | 1.7−8.3 | <0.0001 |
| Increased | 113/1438(7.9) | 27/667(4.1) | 86/771(11.2) | <0.0001 | |
| Lactate dehydrogenase, U/L | 272.5(218.0-345.0) | 263.0(210.0-326.0) | 282.0(227.0-372.0) | 135−214 | <0.0001 |
| Increased | 1110/1444(76.9) | 495/673(73.6) | 615/771(79.8) | 0.005 | |
| Creatine kinase, U/L | 65.5(45.5−113.5) | 65.5(46.0−108.0) | 65.5(44.5−121.5) | 18−198 | 0.50 |
| Increased | 50/588(8.5) | 15/284(5.3) | 35/304(11.5) | 0.007 | |
| C-reactive protein, mg/L | 23.2(4.3−62.3) | 21.0(4.1−54.0) | 25.4(4.8−72.7) | 0.1−3.0 | 0.02 |
| Increased | 1173/1459(80.4) | 546/689(79.3) | 627/770(81.4) | 0.29 | |
| Prothrombin time, s | 13.8(13.2−14.4) | 13.7(13.2−14.3) | 13.9(13.3−14.6) | 11.5−14.5 | 0.0002 |
| Increased | 332/1511(22.0) | 126/711(17.7) | 206/800(25.8) | 0.0002 | |
| APTT, s | 38.8(35.6−42.7) | 38.9(35.8−42.8) | 38.7(35.6−42.5) | 29−42 | 0.49 |
| Increased | 399/1382(28.9) | 188/647(29.1) | 211/735(28.7) | 0.89 | |
| D-dimer, mg/L | 0.7(0.4−1.6) | 0.6(0.4−1.4) | 0.9(0.4−1.9) | 0−0.5 | 0.008 |
| Increased | 956/1484(64.4) | 411/698(58.9) | 545/786(69.3) | <0.0001 | |
| Thrombin time, s | 16.7(15.9−17.5) | 16.4(15.8−17.4) | 16.8(15.9−17.8) | 14−19 | 0.0002 |
| Increased | 95/1382(6.9) | 43/647(6.7) | 52/735(7.1) | 0.75 | |
| Procalcitonin, ng/mL | 0.06(0.03−0.09) | 0.05(0.03−0.08) | 0.06(0.04−0.1) | 0.02−0.05 | 0.003 |
| Increased | 655/1285(51.0) | 279/618(45.2) | 376/667(56.4) | <0.0001 | |
Data are medians (IQR) or No./total No. (%).COVID-19, coronavirus disease 2019, APTT, activated partial thromboplastin time; IQR, inter-quartile ranges.